Stacking Up ARQT Against Its Peers – Is It Still a Buy?
Here is how Arcutis Biotherapeutics (ARQT) stacks up against its peers in size, valuation, growth and margin.
- ARQT’s operating margin of -32.6% is negative, and lowest among peers; REGN has 27.0%.
- ARQT’s revenue growth of 99.5% in the last 12 months is strong, outpacing VRTX, ARGX, REGN, ALNY, AMGN.
- ARQT gained 97.2% in the past year and trades at a PE of -22.8, outperforming its peers.
As a quick background, Arcutis Biotherapeutics provides innovative dermatological treatments, including a topical roflumilast cream for psoriasis and atopic dermatitis, with ongoing development of a topical foam formulation, ARQ-154.
| ARQT | VRTX | ARGX | REGN | ALNY | AMGN | |
|---|---|---|---|---|---|---|
| Market Cap ($ Bil) | 2.1 | 100.8 | 39.9 | 61.0 | 59.2 | 157.4 |
| Revenue ($ Bil) | 0.3 | 11.4 | 2.6 | 14.2 | 2.3 | 34.9 |
| PE Ratio | -22.8 | 27.7 | 37.5 | 13.7 | -219.7 | 23.8 |
| LTM Revenue Growth | 99.5% | 10.5% | 83.2% | 5.4% | 17.2% | 12.9% |
| LTM Operating Margin | -32.6% | -1.7% | 8.3% | 27.0% | -4.9% | 23.5% |
| LTM FCF Margin | -30.8% | 30.6% | – | 25.0% | -3.2% | 30.4% |
| 12M Market Return | 97.2% | -18.3% | 26.0% | -51.1% | 70.3% | -6.7% |
Why does this matter? ARQT just went up 18% in a week – peer comparison puts stock performance, valuation, and financials in context – highlighting whether it is truly outperforming, lagging behind, and above all – can this continue? Read Buy or Sell ARQT Stock to see if Arcutis Biotherapeutics holds up as a quality investment. Furthermore, there is always a risk of fall after a strong rally – see how the stock has dipped and recovered in the past through ARQT Dip Buyer Analysis lens.
While peer comparison is critical Trefis High Quality Portfolio evaluates much more, and is designed to reduce stock-specific risks while giving upside exposure.
- Salesforce’s Pivot: Why “Agentforce” Matters More Than the Earnings Beat
- RBRK Stock Analysis: Strong Growth Meets Rich Valuation
- Why Zscaler’s 27% Crash Is the Ultimate Test for Software Investors
- Snowflake Stock: AI Winner?
- Will The Rally In SMX Stock Continue?
- Applied Digital Stock: A $9 Billion Bet on the AI Buildout
Revenue Growth Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| ARQT | 99.5% | 229.7% | 1517.1% | ∞% |
| VRTX | 10.5% | 11.7% | 10.5% | 17.9% |
| ARGX | 83.2% | 78.6% | 198.6% | -17.4% |
| REGN | 5.4% | 8.3% | 7.8% | -24.3% |
| ALNY | 17.2% | 23.0% | 76.2% | 22.9% |
| AMGN | 12.9% | 18.6% | 7.1% | 1.3% |
Operating Margin Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| ARQT | -32.6% | -65.3% | -404.5% | -8183.0% |
| VRTX | -1.7% | -2.1% | 38.3% | 47.6% |
| ARGX | 8.3% | -0.8% | -34.3% | -176.2% |
| REGN | 27.0% | 28.1% | 30.9% | 38.9% |
| ALNY | -4.9% | -7.9% | -15.4% | -75.7% |
| AMGN | 23.5% | 21.7% | 28.0% | 36.3% |
PE Ratio Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| ARQT | -19.1 | -12.0 | -0.9 | -2.6 |
| VRTX | 31.4 | -193.9 | 29.0 | 22.3 |
| ARGX | 31.6 | 44.2 | -73.7 | -29.0 |
| REGN | 12.4 | 17.4 | 23.7 | 17.8 |
| ALNY | -156.8 | -108.0 | -54.3 | -25.6 |
| AMGN | 22.7 | 34.2 | 22.9 | 21.6 |
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.